Ny behandling af kronisk hepatitis B

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Ny behandling af kronisk hepatitis B. / Andersen, Ellen Sloth; Weis, Nina M; Weis, Nina M.

In: Ugeskrift for Laeger, Vol. 170, No. 48, 2008, p. 3937-9.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Andersen, ES, Weis, NM & Weis, NM 2008, 'Ny behandling af kronisk hepatitis B', Ugeskrift for Laeger, vol. 170, no. 48, pp. 3937-9.

APA

Andersen, E. S., Weis, N. M., & Weis, N. M. (2008). Ny behandling af kronisk hepatitis B. Ugeskrift for Laeger, 170(48), 3937-9.

Vancouver

Andersen ES, Weis NM, Weis NM. Ny behandling af kronisk hepatitis B. Ugeskrift for Laeger. 2008;170(48):3937-9.

Author

Andersen, Ellen Sloth ; Weis, Nina M ; Weis, Nina M. / Ny behandling af kronisk hepatitis B. In: Ugeskrift for Laeger. 2008 ; Vol. 170, No. 48. pp. 3937-9.

Bibtex

@article{aba1ea8b1f9143a58ae6be092c376f84,
title = "Ny behandling af kronisk hepatitis B",
abstract = "Worldwide, 350 million people are infected with chronic hepatitis B. Over the last few years, it has been possible to treat chronic hepatitis B. Treatment very often consists of nucleos(t)ide analogs and in a few cases of pegylated alpha-interferon. In 2007, a new nucleoside analog, Telbivudine, was approved to treat chronic hepatitis B. In phase II and ongoing phase III studies, Telbivudine has proven more effective than the nucleoside analog, Lamivudine, which was very often used up until recently. Udgivelsesdato: 2008-Nov-24",
author = "Andersen, {Ellen Sloth} and Weis, {Nina M} and Weis, {Nina M}",
year = "2008",
language = "Dansk",
volume = "170",
pages = "3937--9",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "48",

}

RIS

TY - JOUR

T1 - Ny behandling af kronisk hepatitis B

AU - Andersen, Ellen Sloth

AU - Weis, Nina M

AU - Weis, Nina M

PY - 2008

Y1 - 2008

N2 - Worldwide, 350 million people are infected with chronic hepatitis B. Over the last few years, it has been possible to treat chronic hepatitis B. Treatment very often consists of nucleos(t)ide analogs and in a few cases of pegylated alpha-interferon. In 2007, a new nucleoside analog, Telbivudine, was approved to treat chronic hepatitis B. In phase II and ongoing phase III studies, Telbivudine has proven more effective than the nucleoside analog, Lamivudine, which was very often used up until recently. Udgivelsesdato: 2008-Nov-24

AB - Worldwide, 350 million people are infected with chronic hepatitis B. Over the last few years, it has been possible to treat chronic hepatitis B. Treatment very often consists of nucleos(t)ide analogs and in a few cases of pegylated alpha-interferon. In 2007, a new nucleoside analog, Telbivudine, was approved to treat chronic hepatitis B. In phase II and ongoing phase III studies, Telbivudine has proven more effective than the nucleoside analog, Lamivudine, which was very often used up until recently. Udgivelsesdato: 2008-Nov-24

M3 - Tidsskriftartikel

VL - 170

SP - 3937

EP - 3939

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 48

ER -

ID: 34160162